224 related articles for article (PubMed ID: 36773395)
1. Over-the-counter fish oil supplementation and pro-resolving and pro-inflammatory lipid mediators in rheumatoid arthritis.
Marchand NE; Choi MY; Oakes EG; Cook NR; Stevens E; Gomelskaya N; Kotler G; Manson JE; Lasky-Su J; Mora S; Lee IM; Tatituri R; Costenbader KH
Prostaglandins Leukot Essent Fatty Acids; 2023 Mar; 190():102542. PubMed ID: 36773395
[TBL] [Abstract][Full Text] [Related]
2. Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial.
See VHL; Mas E; Prescott SL; Beilin LJ; Burrows S; Barden AE; Huang RC; Mori TA
Br J Nutr; 2017 Dec; 118(11):971-980. PubMed ID: 29173199
[TBL] [Abstract][Full Text] [Related]
3. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation.
Norris PC; Skulas-Ray AC; Riley I; Richter CK; Kris-Etherton PM; Jensen GL; Serhan CN; Maddipati KR
Sci Rep; 2018 Dec; 8(1):18050. PubMed ID: 30575798
[TBL] [Abstract][Full Text] [Related]
4. Specialised pro-resolving mediators of inflammation in inflammatory arthritis.
Barden AE; Moghaddami M; Mas E; Phillips M; Cleland LG; Mori TA
Prostaglandins Leukot Essent Fatty Acids; 2016 Apr; 107():24-9. PubMed ID: 27033423
[TBL] [Abstract][Full Text] [Related]
5. Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin.
Barden AE; Mas E; Croft KD; Phillips M; Mori TA
Am J Clin Nutr; 2015 Dec; 102(6):1357-64. PubMed ID: 26561623
[TBL] [Abstract][Full Text] [Related]
6. Effects of postnatal omega-3 fatty acid supplementation on offspring pro-resolving mediators of inflammation at 6 months and 5 years of age: A double blind, randomized controlled clinical trial.
See VHL; Mas E; Prescott SL; Beilin LJ; Burrows S; Barden AE; Huang RC; Mori TA
Prostaglandins Leukot Essent Fatty Acids; 2017 Nov; 126():126-132. PubMed ID: 29031390
[TBL] [Abstract][Full Text] [Related]
7. Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid.
Markworth JF; Kaur G; Miller EG; Larsen AE; Sinclair AJ; Maddipati KR; Cameron-Smith D
FASEB J; 2016 Nov; 30(11):3714-3725. PubMed ID: 27461565
[TBL] [Abstract][Full Text] [Related]
8. Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors.
Keelan JA; Mas E; D'Vaz N; Dunstan JA; Li S; Barden AE; Mark PJ; Waddell BJ; Prescott SL; Mori TA
Reproduction; 2015 Feb; 149(2):171-8. PubMed ID: 25504868
[TBL] [Abstract][Full Text] [Related]
9. Quantitative profiling of inflammatory and pro-resolving lipid mediators in human adolescents and mouse plasma using UHPLC-MS/MS.
Hartling I; Cremonesi A; Osuna E; Lou PH; Lucchinetti E; Zaugg M; Hersberger M
Clin Chem Lab Med; 2021 Oct; 59(11):1811-1823. PubMed ID: 34243224
[TBL] [Abstract][Full Text] [Related]
10. E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition.
Serhan CN; Libreros S; Nshimiyimana R
Semin Immunol; 2022 Jan; 59():101597. PubMed ID: 35227568
[TBL] [Abstract][Full Text] [Related]
11. Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B
Welty FK; Schulte F; Alfaddagh A; Elajami TK; Bistrian BR; Hardt M
FASEB J; 2021 Apr; 35(4):e21448. PubMed ID: 33749913
[TBL] [Abstract][Full Text] [Related]
12. Synbiotic
Speckmann B; Wagner T; Jordan PM; Werz O; Wilhelm M; Tom Dieck H; Schön C
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732601
[TBL] [Abstract][Full Text] [Related]
13. Pathway Markers for Pro-resolving Lipid Mediators in Maternal and Umbilical Cord Blood: A Secondary Analysis of the Mothers, Omega-3, and Mental Health Study.
Mozurkewich EL; Greenwood M; Clinton C; Berman D; Romero V; Djuric Z; Qualls C; Gronert K
Front Pharmacol; 2016; 7():274. PubMed ID: 27656142
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease.
Mas E; Barden A; Burke V; Beilin LJ; Watts GF; Huang RC; Puddey IB; Irish AB; Mori TA
Clin Nutr; 2016 Apr; 35(2):331-336. PubMed ID: 25908532
[TBL] [Abstract][Full Text] [Related]
15. EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study.
So J; Wu D; Lichtenstein AH; Tai AK; Matthan NR; Maddipati KR; Lamon-Fava S
Atherosclerosis; 2021 Jan; 316():90-98. PubMed ID: 33303222
[TBL] [Abstract][Full Text] [Related]
16. Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements.
Schaller MS; Zahner GJ; Gasper WJ; Harris WS; Conte MS; Hills NK; Grenon SM
J Clin Lipidol; 2017; 11(5):1289-1295. PubMed ID: 28778393
[TBL] [Abstract][Full Text] [Related]
17. Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake.
Calder PC
Biochimie; 2020 Nov; 178():105-123. PubMed ID: 32860894
[TBL] [Abstract][Full Text] [Related]
18. Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial).
Ramirez JL; Gasper WJ; Khetani SA; Zahner GJ; Hills NK; Mitchell PT; Sansbury BE; Conte MS; Spite M; Grenon SM
J Surg Res; 2019 Jun; 238():164-174. PubMed ID: 30771686
[TBL] [Abstract][Full Text] [Related]
19. Docosahexaenoic acid in the treatment of rheumatoid arthritis: A double-blind, placebo-controlled, randomized cross-over study with microalgae vs. sunflower oil.
Dawczynski C; Dittrich M; Neumann T; Goetze K; Welzel A; Oelzner P; Völker S; Schaible AM; Troisi F; Thomas L; Pace S; Koeberle A; Werz O; Schlattmann P; Lorkowski S; Jahreis G
Clin Nutr; 2018 Apr; 37(2):494-504. PubMed ID: 28302406
[TBL] [Abstract][Full Text] [Related]
20. Equal bioavailability of omega-3 PUFA from Calanus oil, fish oil and krill oil: A 12-week randomized parallel study.
Vosskötter F; Burhop M; Hahn A; Schuchardt JP
Lipids; 2023 May; 58(3):129-138. PubMed ID: 36960737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
